Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) management will conduct a conference call for 9th November 2020 at 8:30 AM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.interceptpharma.com
Earnings Expectation
Intercept Pharmaceuticals, Inc. is expected to report third quarter earnings results, before market open, on Monday 9th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 1.93 per share from revenue of $ 78.63 million. Looking ahead, the full year loss are expected at $ 8.47 per share on the revenues of $ 311.93 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 300.00 million ~ $ 320.00 million
Click Here For More Historical Outlooks Of Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development.
